Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU

Inclusion Criteria:

- Subject has been admitted to the institution's EMU for seizure characterization or
pre-surgical evaluation, or such admission is planned within 28 days

- Subject body weight is ≥ 40 kg to ≤ 125 kg (inclusive)

- Subject has an established diagnosis of partial or generalized epilepsy

Exclusion Criteria:

- Subject has history of status epilepticus in the 6 months prior to Screening

- Subject has a progressive neurological disorder such as brain tumor, demyelinating
disease, or degenerative central nervous system (CNS) disease that is likely to
progress in the next 12 months

- Subject has respiratory failure (or is at risk for respiratory failure) or other
severe cardiorespiratory disease with New York Heart Association Class III or IV
functional status, or requires supplemental oxygen

- Subject has acute narrow-angle glaucoma

- Subject is receiving chronic benzodiazepine treatment (defined as an average of ≥ 4
administrations per week) and cannot safely withdraw from such treatment within the
washout period prior to treatment